The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | The impact of genetic abnormalities on treatment decisions in CLL
Antonio Cuneo, MD, St. Anna University Hospital, Ferrara, Italy, discusses the importance of genomic testing prior to treatment initiation in chronic lymphocytic leukemia (CLL), highlighting the impact of TP53 mutations, 17p deletion (del 17p), and immunoglobulin gene (IgG) mutations on treatment decisions, and outlining methods used to detect these abnormalities. According to Dr Cuneo, patients who do not carry IgG mutations, or patients who carry del 17p or TP53 mutations should not be treated with chemoimmunotherapy. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
